Omega Diagnostics is expected to move into profit next year.
In the first half of this year, the allergy division increased its revenues by one-quarter, while the infectious disease division revenues fell by one-third. Food intolerance generates the majority of revenues and this division increased its revenues by 6% to £4.46m. Total group revenues from continuing operations were £5.23m.
VISITECT CD4 is expected to generate £500,000 in revenues this year and £2m in the year to March 2021. This provides the upside for the group.
© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds